Gram-negative bacterial pneumonia: Aetiology and management

Current Opinion in Pulmonary Medicine

Volumn 12, Issue 3, 2006, Pages 198-204

  Koulenti, Despoina ^a   Rello, Jordi ^a  

^a HOSPITAL UNIVERSITARI JOAN XXIII   (Spain)

Author keywords

Community acquired pneumonia; Gram negative bacteria; Hospital acquired pneumonia; Ventilator associated pneumonia

Indexed keywords

AMIKACIN; AMINOGLYCOSIDE; ANTIBIOTIC AGENT; BETA LACTAM ANTIBIOTIC; CARBAPENEM; CEFEPIME; CEFTAZIDIME; COLISTIN; GENTAMICIN; IMIPENEM; MEROPENEM; PIPERACILLIN PLUS TAZOBACTAM; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RIFAMPICIN; TIGECYCLINE; TOBRAMYCIN; ANTIINFECTIVE AGENT;

ANTIBIOTIC THERAPY; BACTERIAL PNEUMONIA; DRUG MECHANISM; GRAM NEGATIVE BACTERIUM; GRAM NEGATIVE INFECTION; HUMAN; IMMUNOCOMPETENCE; INFECTION RATE; INFECTION RISK; NONHUMAN; PATHOGENESIS; PRESCRIPTION; PSEUDOMONAS AERUGINOSA; REVIEW; TREATMENT DURATION; MICROBIOLOGY; TREATMENT OUTCOME;

ANTI-INFECTIVE AGENTS; GRAM-NEGATIVE BACTERIAL INFECTIONS; HUMANS; PNEUMONIA, BACTERIAL; TREATMENT OUTCOME;

EID: 33745034053     PISSN: 10705287     EISSN: 15316971     Source Type: Journal    
DOI: 10.1097/01.mcp.0000219269.73180.5d     Document Type: Review

References (49)

1. Rello J, Diaz E, Rodriguez A. Etiology of ventilator-associated pneumonia. Clin Chest Med 2005; 26:87-95. A thorough review of the pathogens that cause VAP, with particular emphasis on risk factors, attributable mortality, resistance, and the implications for management.
2. Park DR. The microbiology of ventilator-associated pneumonia. Respir Care 2005; 50:742-763. An excellent and in depth review of the microbiology of VAP.
3. Bodi M, Rodriguez A, Sole-Violan J, et al. Antibiotic prescription for community-acquired pneumonia in the intensive care unit: impact of adherence to Infectious Diseases Society of America guidelines on survival. Clin Infect Dis 2005; 41:1709-1716. A very important large prospective multicentre trial (33 hospitals, 529 patients) of patients with severe CAP. It is the first study that evaluates the variables that are associated with mortality in patients with severe CAP.
4. Arancibia F, Bauer TT, Ewig S, et al. Community-acquired pneumonia due to Gram-negative bacteria and Pseudomonas aeruginosa: incidence, risk, and prognosis. Arch Intern Med 2002; 162:1849-1858.
5. Yoshimoto A, Nakamura H, Fujimura M, Nakao S. Severe community-acquired pneumonia in an intensive care unit: risk factors for mortality. Intern Med 2005; 44:710-716.
6. Giantsou E, Liratzopoulos N, Efraimidou E, et al. Both early-onset and late-onset ventilator associated pneumonia are caused mainly by potentially multiresistant bacteria. Intensive Care Med 2005; 31:1488-1494. A prospective study of 437 patients with VAP diagnosed with bronchoalveolar lavage and quantitative cultures that compares the causative pathogens in early and late onset VAP.
7. Boots RJ, Lipman J, Bellomo R, et al. The spectrum of practice in the diagnosis and management of pneumonia in patients requiring mechanical ventilation. Australian and New Zealand practice in intensive care (ANZPIC II) Anaesth Intensive Care 2005; 33:87-100. An important large multicentre prospective study of ventilated patients with pneumonia in 14 ICUs in Australia and New Zealand, which included 476 episodes of pneumonia (48% CAP, 24% hospital-acquired pneumonia, 28% VAP).
8. Gaynes R, Edwards JR, and the National Nosocomial Infections Surveillance System. Overview of nosocomial infections caused by Gram-negative bacilli. Clin Infect Dis 2005; 41:848-854. In this study data from the National Nosocomial Infections Surveillance System from 1986-2003 were analysed to determine the epidemiology of Gram-negative bacilli in ICUs for the most frequent types of hospital-acquired infection.
9. Cisneros JM, Rodriguez-Bano J, Fernandez-Cuenca F, et al. Risk-factors for the acquisition of imipenem-resistant Acinetobacter baumannii in Spain: a nationwide study. Clin Microbiol Infect 2005; 11:874-879. A nationwide cohort study (25 Spanish hospitals) that investigated potential risk factors for the acquisition of imipenem-resistant A. baumannii.
10. Wright MO. Greater Baltimore Chapter of the Association for Professionals in Infection Control and Epidemiology (APIC). Multi-resistant Gram-negative organisms in Maryland: a statewide survey of resistant Acinetobacter baumannii. Am J Infect Control 2005; 33:419-421. A large, statewide study (70 hospitals in Maryland) which assessed the frequency of multidrug-resistant A. baumannii.
11. Fowler RA, Flavin KE, Barr J. Variability in antibiotic prescribing patterns and outcomes in patients with clinically suspected ventilator- associated pneumonia. Chest 2003; 123:835-844.
12. Micek ST, Lloyd AE, Ritchie DJ, et al. Pseudomonas aeruginosa bloodstream infection: importance of appropriate initial antimicrobial treatment. Antimicrob Agents Chemother 2005; 49:1306-1311. A very important retrospective cohort analysis of 305 patients with Pseudomonas aeruginosa bloodstream infection which concluded that inappropriate initial empirical antimicrobial treatment is associated with greater hospital mortality.
13. Drusano GL. Prevention of resistance: a goal for dose selection for antimicrobial agents. Clin Infect Dis 2003; 36:S42-S50.
14. Burgess DS, Frei CR. Comparison of beta-lactam regimens for the treatment of Gram-negative pulmonary infections in the intensive care unit based on pharmacokinetics/pharmacodynamics. Antimicrob Chemother 2005; 56:893-898. This study utilized pharmacokinetics/pharmacodynamics to compare β-lactam regimens for the empirical and definitive treatment of Gram-negative pulmonary infections in the ICU, using susceptibility data from the 2002 Intensive Care Unit Surveillance System (minimal inhibitory concentrations for 2408 Gram-negative isolates) and pharmacokinetic parameters from published human studies.
15. Paterson DL. Collateral damage from cephalosporin or quinolone antibiotic therapy. Clin Infect Dis 2004; 38 (suppl 4):S341-S345.
16. Nseir S, DiPompeo C, Soubrier S, et al. First-generation fluoroquinolone use and subsequent emergence of multiple drug-resistance bacteria in the intensive care unit. Crit Care Med 2005; 33:283-289. A prospective observational cohort study and a case-control study that was conducted in a 30-bed ICU during a 15-month period with the objective to determine the relationship between fluoroquinolone use and subsequent emergence of multidrug-resistant bacteria in the ICU.
17. Livermore DM. Multiple mechanisms of antimicrobial resistance in Pseudomonas aeruginosa: our worst nightmare? Clin Infect Dis 2002; 34:634-640.
18. Niederman NS. Reexamining quinolone use in the intensive care unit: use them right or lose the fight against resistant bacteria. Crit Care Med 2005; 33:443-444.
19. American Thoracic Society. Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia. American Thoracic Society Documents. Am J Respir Crit Care Med 2005; 171:388-416. The official statement of the American Thoracic Society and the Infectious Diseases Society of America which was approved by the American Thoracic Society Board of Directors in December 2004 and the IDSA Guideline Committee on October 2004.
20. Paul M, Benuri-Silbiger I, Soares-Weiser K, Leibovici L. Beta lactam monotherapy versus beta lactam-aminoglycoside combination therapy for sepsis in immunocompetent patients: systematic review and meta-analysis of randomised trials. BMJ 2004; 328:668. A large meta-analysis of all randomized trials until 2003 (64 trials with 7586 patients were included) of β-lactam monotherapy compared with β-lactam/aminoglycoside combination therapy for patients without neutropenia who fulfilled the criteria for sepsis.
21. Safdar N, Handelsman J, Maki DG. Does combination antimicrobial therapy reduce mortality in Gram-negative bacteraemia? A meta-analysis. Lancet Infect Dis 2004; 4:519-527. A meta-analysis of published studies (17 studies met the inclusion criteria: five prospective cohort studies, two prospective randomized trials, and 10 retrospective cohort studies) to determine whether a combination of two or more antimicrobials reduces mortality in patients with Gram-negative bacteremia.
22. Garnacho J, Sole-Violan J, Sa-Borges M, et al. Clinical impact of pneumonia caused by Acinetobacter baumannii in intubated patients: a matched cohort study. Crit Care Med 2003; 31:2478-2482.
23. Garnacho-Montero J, Ortiz-Leyba C, Fernandez-Hinojosa E, et al. Acinetobacter baumannii ventilator-associated pneumonia: epidemiological and clinical findings. Intensive Care Med 2005; 31:649-655. A prospective study of 81 episodes of VAP (41 by A. baumannii; 26 by imipenemresistance), with specific analysis of imipenem-resistant episodes, to investigate prognostic factors and predictors of A. baumannii isolation in VAP.
24. Bernabeu-Wittel M, Pichardo C, Garcia-Curiel A, et al. Pharmacokinetic/pharmacodynamic assessment of the in-vivo efficacy of imipenem alone or in combination with amikacin for the treatment of experimental multiresistant Acinetobacter baumannii pneumonia. Clin Microbiol Infect 2005; 11:319-325. A guinea-pig pneumonia model involving imipenem-susceptible and imipenem-resistant strains of A. baumannii was used to assess the in-vitro and in-vivo activities of imipenem, alone or in combination with amikacin, and the pharmacokinetic and pharmacodynamic parameters.
25. Montero A, Ariza J, Corbella X, et al. Antibiotic combinations for serious infections caused by carbapenem-resistant Acinetobacter baumannii in a mouse pneumonia model. J Antimicrob Chemother 2004; 54:1085-1091. This study used a mouse pneumonia model to identify antibiotic combinations that were valid against carbapenem-resistant A. baumannii.
26. Montero A, Ariza J, Corbella X, et al. Efficacy of colistin versus beta-lactams, aminoglycosides, and rifampin as monotherapy in a mouse model of pneumonia caused by multiresistant Acinetobacter baumannii. Antimicrob Agents Chemother 2002; 46:1946-1952.
27. Garnacho-Montero J, Ortiz-Leyba C, Jimenez-Jimenez FJ, et al. Treatment of multidrug-resistant Acinetobacter baumannii ventilator-associated pneumonia (VAP) with intravenous colistin: a comparison with imipenem-susceptible VAP. Clin Infect Dis 2003; 36:1111-1118.
28. Pachon-Ibanez ME, Jimenez-Mejias ME, Pichardo C, et al. Activity of tigecycline (GAR-936) against Acinetobacter baumannii strains, including those resistant to imipenem. Antimicrob Agents Chemother 2004; 48:4479-4481.
29. Rello J. Pharmacokinetics, pharmacodynamics, safety and tolerability of tigecycline. J Chemother 2005; 17 (suppl 1):12-22. An in-depth review of tigecycline.
30. Hoban DJ, Bouchillon SK, Johnson BM, et al. In vitro activity of tigecycline against 6792 Gram-negative and Gram-positive clinical isolates from the global Tigecycline Evaluation and Surveillance Trial (TEST Program, 2004). Diagn Microbiol Infect Dis 2005; 52:215-227. This study evaluated the activity of tigecycline and commonly used antimicrobials against 6792 clinical isolates from 40 study centers in 11 countries.
31. Fritsche TR, Strabala PA, Sader HS, et al. Activity of tigecycline tested against a global collection of Enterobacteriaceae, including tetracycline-resistant isolates. Diagn Microbiol Infect Dis 2005; 52:209-213.
32. Fritsche TR, Sader HS, Stilwell MG, et al. Antimicrobial activity of tigecycline tested against organisms causing community-acquired respiratory tract infection and nosocomial pneumonia. Diagn Microbiol Infect Dis 2005; 52:187-193. In this study, tigecycline spectrum and potency were evaluated against a global collection of pathogens (2000-2004) recovered from community-acquired respiratory infections (7580 strains) or from hospitalized patients with pneumonia (3183 strains).
33. Masterton RG, Turner PJ. Trends in antimicrobial susceptibility in UK centres: the MYSTIC Programme (1997-2002). Int J Antimicrob Agents 2006; 27:69-72. In this study trends in antimicrobial susceptibilities in three UK centers participating in the MYSTIC Program were examined from 1997 to 2002.
34. Jones RN, Mendes C, Turner PJ, Masterton R. An overview of the Meropenem Yearly Susceptibility Test Information Collection (MYSTIC) Program: 1997-2004. Diagn Microbiol Infect Dis 2005; 53:247-256. This overview provides a summary of the Meropenem Yearly Susceptibility Test Information Collection (MYSTIC) Program over an 8-year period from1997 to 2004.
35. Paterson DL, Ko WC, Von Gottberg A, et al. International prospective study of Klebsiella pneumoniae bacteremia: implications of extended-spectrum beta-lactamase production in nosocomial Infections. Ann Intern Med 2004; 40:26-32. An international multicentre prospective observational study that was conducted to determine whether microbiology laboratories should report the presence of ESBLs and to establish the infection-control implications of ESBL-producing organisms.
36. Gonlugur U, Bakici MZ, Akkurt I, Efeoglu T. Antibiotic susceptibility patterns among respiratory isolates of Gram-negative bacilli in a Turkish university hospital. BMC Microbiol 2004; 4:32.
37. Paterson DL, Ko WC, Von Gottberg A, et al. Antibiotic therapy for Klebsiella pneumoniae bacteremia: implications of production of extended-spectrum beta-lactamases. Clin Infect Dis 2004; 39:31-37. A large international multicentre study.
38. Smith Moland E, Hanson ND, Herrera VL, et al. Plasmid-mediated, carbapenem-hydrolysing beta-lactamase, KPC-2, in Klebsiella pneumoniae isolates. J Antimicrob Chemother 2003; 51:711-714.
39. Chastre J, Wolff M, Fagon JY, et al. Comparison of 8 vs. 15 days of antibiotic therapy for ventilator-associated pneumonia in adults. JAMA 2003; 290:2588-2598.
40. Micek ST, Ward S, Fraser VJ, Kollef MH. A randomized controlled trial of an antibiotic discontinuation policy for clinically suspected ventilator-associated pneumonia. Chest 2004; 125:1791-1799. A prospective randomized controlled clinical trial (290 patients with VAP from a university-affiliated hospital medical ICU were included) that evaluated an antibiotic discontinuation policy for clinically suspected VAP.
41. Vidaur L, Gualis B, Rodriguez A, et al. Clinical resolution in patients with suspicion of ventilator-associated pneumonia: a cohort study comparing patients with and without acute respiratory distress syndrome. Crit Care Med 2005; 33:1248-1253. A prospective, observational cohort study which compared 75 episodes of VAP without with 20 episodes of VAP with acute respiratory distress syndrome. It is the first study that reports differences in the clinical resolution patterns of VAP between patients with and without acute respiratory distress syndrome at pneumonia onset.
42. Pier G. Application of vaccine technology to prevention of Pseudomonas aeruginosa infections. Expert Rev Vaccines 2005; 4:645-656. An excellent and in-depth review of the variety of active vaccination approaches to preventing P. aeruginosa infections.
43. Tsubery H, Yaakov H, Cohen S, et al. Neopeptide antibiotics that function as opsonins and membrane-permeabilizing agents for Gram-negative bacteria. Antimicrob Agents Chemother 2005; 49:3122-3128.
44. McMullin BB, Chittock DR, Roscoe DL, et al. The antimicrobial effect of nitric oxide on the bacteria that cause nosocomial pneumonia in mechanically ventilated patients in the intensive care unit. Respir Care 2005;50:1451-1456. The objective of this study was to determine the antimicrobial effect of exogenous gaseous NO in vitro against organisms from culture collections and pathogens derived from tracheal aspirates of mechanically ventilated patients with pneumonia in an ICU.
45. Branger J, Knapp S, Weijer S, et al. Role of Toll-like receptor 4 in Gram-positive and Gram-negative pneumonia in mice. Infect Immun 2004; 72:788-794. This study tried to determine the role of TLR-4 in the immune response in Gram-positive and Gram-negative pneumonia using a murine model.
46. Knapp S, Wieland CW, Florquin S, et al. Differential roles of CD14 and Toll-like receptors 4 and 2 in murine Acinetobacter pneumonia. Am J Respir Crit Care Med 2006; 173:122-129. This study tried to gain first insight into the role of CD14 and TLRs 4 and 2 in host responses to A. baumannii pneumonia using a murine model defective in the respective genes.
47. Schurr JR, Young E, Byrne P, et al. Central role of toll-like receptor 4 signaling and host defense in experimental pneumonia caused by Gram-negative bacteria. Infect Immun 2005; 73:532-545. In this study the role of TLR-4 signalling in coordinating gene expression was assessed by gene-expression profiling in lung tissue in a mouse model of experimental K. pneumoniae pneumonia.
48. Kuzmenko AI, Wu H, Wan S, McCormack FX. Surfactant protein A is a principal and oxidation-sensitive microbial permeabilizing factor in the alveolar lining fluid. J Biol Chem 2005; 280:25913-25919. This study investigated the physiologic importance of surfactant protein A's ability to kill some Gram-negative organisms by increasing membrane permeability and the effect of oxidative stress on the antimicrobial functions of surfactant protein A.
49. Vitkauskiene A, Scheuss S, Sahly H, et al. Pseudomonas aeruginosa strains from nosocomial pneumonia are more serum resistant than P. aeruginosa strains from non-infectious respiratory colonization processes. Infection 2005; 33:356-361.